Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
Gilead and Merck tested a new HIV medicine that patients take once a week instead of every day, and it worked as well as regular pills over a year. This is exciting because if doctors approve it, many people might want to use it, which could be a big business win for both companies.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.